Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of two dosing regimens of GSK2402968 in ambulant boys with Duchenne muscular dystrophy
NL-OMON34487Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Feb 2011
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of drisapersen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by GSK. Primary endpoint: 6-minute walk distance. Started Feb 2011; status: active, not recruiting.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON34487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34487.